Agenus (AGEN) said Monday that data from a 70-patient group in a Phase 1b study of botensilimab combined with balstilimab to treat colorectal cancer showed...
Agenus (AGEN) late Friday registered with the US Securities and Exchange Commission for the potential resale of up to about 2 million common shares by some...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 3 Forbes Road Lexington, Massachusetts 02421-7305 |
| Phone | +1.781.674.4400 |
| Number of Employees | 294 |
| Recent SEC Filing | 01/09/2023 4 |
| Chairman & Chief Executive Officer | Garo H. Armen |
| Chief Financial & Accounting Officer, VP-Finance | Christine M. Klaskin |
| Chief Medical Officer | Steven O’Day |
| Chief Information Officer | Craig Winter |
| Price Open | $2.58 |
| Previous Close | $2.55 |
| 52 Week Range | $1.25 - 3.37 |
| Market Capitalization | $791.0 M |
| Shares Outstanding | 304.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/07/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.81 |
| Beta vs. S&P 500 | N/A |
| Revenue | $36.8 M |
| Net Profit Margin | -238.59% |
| Return on Equity | -2,585.10% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
